Hi All,
Something interesting. Sparsentan has been accepted for priority review by the FDA for a NDA for IgA Nephropathy. This was off interim results in their Ph3 pivotal trial following 36 weeks of treatment. Sound familiar (as in trial design)?
https://www.globenewswire.com/news-release/2021/08/16/2280963/0/en/Travere-Therapeutics-Announces-Positive-Topline-Interim-Results-from-the-Ongoing-Phase-3-PROTECT-Study-of-Sparsentan-in-IgA-Nephropathy.html
https://www.globenewswire.com/news-release/2022/05/16/2443695/0/en/Travere-Therapeutics-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Sparsentan-for-the-Treatment-of-IgA-Nephropathy.html
Travere’s FSGS Ph3 met primary endpoint data for interim analysis but the FDA wanted more data for priority review.
https://www.globenewswire.com/news-release/2022/05/17/2445474/0/en/Travere-Therapeutics-Announces-Presentations-of-Abstracts-at-the-59th-ERA-Congress.html
Both trials are ongoing. Travere announced a licencing deal with Vifor (CSL) for IgA Nephropathy last September. This is just for one kidney indication for Spartensan.
https://www.fiercebiotech.com/biotech/vifor-doles-out-55m-upfront-to-license-travere-s-late-stage-kidney-asset-slated-for
It’s been a long haul for Travere as well, but I guess patience pays off.
DMX-200 has been shown to be synergistic in pre-clinical work with endothelin A inhibitors eg sparsentan (ie replacing the ARB with Spartensan). Probably worth reflecting back on this.
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02356811-3A564106?access_token=83ff96335c2d45a094df02a206a39ff4
GLTAH
- Forums
- ASX - By Stock
- Ann: FDA IND Approval for Phase 3 Study of DMX-200 in FSGS
Hi All,Something interesting. Sparsentan has been accepted for...
-
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $214.4M |
Open | High | Low | Value | Volume |
39.0¢ | 39.0¢ | 37.0¢ | $503.5K | 1.322M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 26318 | 38.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.0¢ | 170072 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 26318 | 0.380 |
6 | 228354 | 0.375 |
6 | 178335 | 0.370 |
4 | 86518 | 0.365 |
4 | 27499 | 0.360 |
Price($) | Vol. | No. |
---|---|---|
0.390 | 170072 | 6 |
0.395 | 90849 | 3 |
0.400 | 144109 | 4 |
0.405 | 86528 | 4 |
0.410 | 56400 | 2 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |